What after Vincent Capponi’s Insider Sale of Cytosorbents (CTSO) Stock?; Nicholas Investment Partners LP Has Increased Its Madden Steven LTD (SHOO) Stake

May 18, 2018 - By Kurt Siggers

Cytosorbents Corporation (NASDAQ:CTSO) Logo

Nicholas Investment Partners Lp increased Madden Steven Ltd (SHOO) stake by 84.2% reported in 2017Q4 SEC filing. Nicholas Investment Partners Lp acquired 61,372 shares as Madden Steven Ltd (SHOO)’s stock declined 7.53%. The Nicholas Investment Partners Lp holds 134,262 shares with $6.27M value, up from 72,890 last quarter. Madden Steven Ltd now has $2.96B valuation. The stock decreased 0.98% or $0.5 during the last trading session, reaching $50.65. About 497,781 shares traded or 3.92% up from the average. Steven Madden, Ltd. (NASDAQ:SHOO) has risen 13.16% since May 18, 2017 and is uptrending. It has outperformed by 1.61% the S&P500.

Yesterday, the Chief Operating Officer of Cytosorbents Corp, Mr. Vincent Capponi, sold number of shares – 7,154, amounting to $64,386 U.S. Dollars, which is based on a market stock price of $9.0 for each share. Vincent filled this sale on May 17, 2018. The document is free at your disposal here at the U.S. SEC website. This transaction decreased his ownership of the Company to 1.06% total market capitalization or 317,551 shares.

Among 7 analysts covering CytoSorbents (NASDAQ:CTSO), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CytoSorbents has $14.0 highest and $7 lowest target. $11.36’s average target is 13.03% above currents $10.05 stock price. CytoSorbents had 16 analyst reports since October 29, 2015 according to SRatingsIntel. H.C. Wainwright maintained the shares of CTSO in report on Tuesday, January 9 with “Buy” rating. Maxim Group initiated Cytosorbents Corporation (NASDAQ:CTSO) on Tuesday, May 24 with “Buy” rating. The firm has “Buy” rating given on Thursday, October 29 by WBB Securities. H.C. Wainwright maintained it with “Buy” rating and $14.0 target in Friday, March 9 report. As per Monday, July 17, the company rating was maintained by Maxim Group. On Tuesday, May 30 the stock rating was maintained by Aegis Capital with “Buy”. The stock of Cytosorbents Corporation (NASDAQ:CTSO) has “Buy” rating given on Tuesday, September 26 by H.C. Wainwright. Maxim Group maintained Cytosorbents Corporation (NASDAQ:CTSO) on Tuesday, August 8 with “Buy” rating. On Thursday, March 8 the stock rating was maintained by Cowen & Co with “Buy”. Maxim Group maintained the shares of CTSO in report on Wednesday, July 5 with “Buy” rating.

The stock increased 6.91% or $0.65 during the last trading session, reaching $10.05. About 789,538 shares traded or 246.31% up from the average. Cytosorbents Corporation (NASDAQ:CTSO) has risen 28.83% since May 18, 2017 and is uptrending. It has outperformed by 17.28% the S&P500.

Investors sentiment increased to 2.89 in 2017 Q4. Its up 1.62, from 1.27 in 2017Q3. It improved, as 5 investors sold Cytosorbents Corporation shares while 4 reduced holdings. 12 funds opened positions while 14 raised stakes. 2.91 million shares or 22.09% more from 2.38 million shares in 2017Q3 were reported. Vanguard Grp owns 851,576 shares or 0% of their US portfolio. Raymond James & Associate reported 100,000 shares. Bank Of America De owns 5,000 shares. State Street Corp has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). Goldman Sachs Inc reported 22,521 shares. Peak6 Investments Lp accumulated 99,744 shares. Susquehanna Gp Llp accumulated 61,909 shares or 0% of the stock. Credit Suisse Ag stated it has 0% in Cytosorbents Corporation (NASDAQ:CTSO). Pnc Serv Group Incorporated invested 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). 46,100 were reported by California Public Employees Retirement Sys. Blackrock, a New York-based fund reported 140,137 shares. Bluecrest Mngmt Limited reported 60,892 shares or 0.01% of all its holdings. Skylands Limited Com has invested 0.61% in Cytosorbents Corporation (NASDAQ:CTSO). 5,874 are owned by Royal Bankshares Of Canada. Tower Rech Cap Ltd Liability Company (Trc) stated it has 778 shares or 0% of all its holdings.

Since January 8, 2018, it had 0 insider purchases, and 8 insider sales for $711,400 activity. The insider BLOCH KATHLEEN P. sold $111,600.

Analysts await Cytosorbents Corporation (NASDAQ:CTSO) to report earnings on August, 6. They expect $-0.13 earnings per share, down 225.00% or $0.09 from last year’s $-0.04 per share. After $-0.10 actual earnings per share reported by Cytosorbents Corporation for the previous quarter, Wall Street now forecasts 30.00% negative EPS growth.

More recent Cytosorbents Corporation (NASDAQ:CTSO) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” on May 18, 2018. Also Seekingalpha.com published the news titled: “Cytosorbents’ (CTSO) CEO Phillip Chan on Q1 2018 Results – Earnings Call Transcript” on May 12, 2018. Streetinsider.com‘s news article titled: “Cytosorbents (CTSO) Reports Addition of Bilirubin and Myoglobin Reduction to EU Approved Indications for Use” with publication date: May 14, 2018 was also an interesting one.

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. The company has market cap of $301.82 million. The Company’s principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It currently has negative earnings. The firm also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

More news for Steven Madden, Ltd. (NASDAQ:SHOO) were recently published by: Businesswire.com, which released: “Steve Madden Announces Participation in the 19” on May 16, 2018. Globenewswire.com‘s article titled: “Detailed Research: Economic Perspectives on Viasat, Cloud Peak Energy, Steven Madden, Entravision …” and published on May 14, 2018 is yet another important article.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.30, from 1.35 in 2017Q3. It turned negative, as 27 investors sold SHOO shares while 65 reduced holdings. 30 funds opened positions while 67 raised stakes. 53.17 million shares or 0.32% less from 53.34 million shares in 2017Q3 were reported. Financial Bank Of New York Mellon Corporation holds 695,932 shares. Northern Corporation holds 0.01% or 919,367 shares in its portfolio. Kennedy Cap Mngmt reported 103,655 shares. Janney Montgomery Scott Ltd Liability Corporation stated it has 15,034 shares or 0.01% of all its holdings. 9,030 were reported by Parallax Volatility Advisers Lp. Hotchkis Wiley Capital Mngmt holds 0% or 9,813 shares. Delta Asset Ltd Company Tn owns 30 shares or 0% of their US portfolio. Fmr Ltd Liability Company has 2.84M shares for 0.02% of their portfolio. Kemnay Advisory Service invested in 28,838 shares or 0.6% of the stock. Principal Financial Group Inc Inc holds 0.02% or 438,485 shares. Huntington Bank has invested 0% of its portfolio in Steven Madden, Ltd. (NASDAQ:SHOO). Wells Fargo And Mn reported 811,421 shares. Millennium Mgmt Ltd Liability Company holds 0.03% or 492,866 shares in its portfolio. State Street has invested 0.01% in Steven Madden, Ltd. (NASDAQ:SHOO). Burney Communication reported 9,424 shares.

Since December 18, 2017, it had 0 insider buys, and 3 insider sales for $2.00 million activity. $192,320 worth of Steven Madden, Ltd. (NASDAQ:SHOO) was sold by Frieders Karla. Rosenfeld Edward R. sold $1.51M worth of stock or 33,000 shares. SINHA AWADHESH K sold $292,663 worth of Steven Madden, Ltd. (NASDAQ:SHOO) on Monday, December 18.

Nicholas Investment Partners Lp decreased Microsoft Corp (NASDAQ:MSFT) stake by 11,502 shares to 50,305 valued at $4.30 million in 2017Q4. It also reduced Knight Swift Transn Hldgs In stake by 7,197 shares and now owns 215,532 shares. Alibaba Group Hldg Ltd (NYSE:BABA) was reduced too.

Steven Madden, Ltd. (NASDAQ:SHOO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts